title: Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire.
abstract: BACKGROUND
  The impact of cytogenetic abnormalities in multiple myeloma after allogeneic stem cell transplantation has not been clearly defined. This study examines whether allogeneic stem cell transplantation could be of benefit for myeloma patients with high-risk cytogenetic abnormalities.
  
  
  METHODS
  This is a retrospective multicenter analysis of the registry of the Société Française de Greffe de Moelle et de Thérapie Cellulaire, including 143 myeloma patients transplanted between 1999 and 2008.
  
  
  RESULTS
  The incidences of cytogenetic abnormalities were 59% for del(13q), 25% for t(4;14), 25% for del(17p) and 4% for t(14;16). When comparing the population carrying an abnormality to that without the same abnormality, no significant difference was found in progression-free survival, overall survival or progression rate. Patients were grouped according to the presence of any of the poor prognosis cytogenetic abnormalities t(4;14), del(17p) or t(14;16) (n=53) or their absence (n=32). No difference in outcomes was observed between these two groups: the 3-year progression-free survival, overall survival and progression rates were 30% versus 17% (P=0.9), 45% versus 39% (P=0.8) and 53% versus 75% (P=0.9), respectively.
  
  
  CONCLUSIONS
  These data indicate that allogeneic stem cell transplantation could potentially be of benefit to high-risk myeloma patients.
authors.affiliation: Hematology Department, University Hospital Pitié-Salpêtrière, Paris, France. damien.roosweil@psl.aphp.fr
authors.forename: Damien
authors.initials: D
authors.lastname: Roos-Weil
authors.forename: Philippe
authors.initials: P
authors.lastname: Moreau
authors.forename: Hervé
authors.initials: H
authors.lastname: Avet-Loiseau
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Golmard
authors.forename: Mathieu
authors.initials: M
authors.lastname: Kuentz
authors.forename: Stéphane
authors.initials: S
authors.lastname: Vigouroux
authors.forename: Gérard
authors.initials: G
authors.lastname: Socié
authors.forename: Sabine
authors.initials: S
authors.lastname: Furst
authors.forename: Jean
authors.initials: J
authors.lastname: Soulier
authors.forename: Steven
authors.initials: S
authors.lastname: Le Gouill
authors.forename: Sylvie
authors.initials: S
authors.lastname: François
authors.forename: Anne
authors.initials: A
authors.lastname: Thiebaut
authors.forename: Agnès
authors.initials: A
authors.lastname: Buzyn
authors.forename: Natacha
authors.initials: N
authors.lastname: Maillard
authors.forename: Ibrahim
authors.initials: I
authors.lastname: Yakoub-Agha
authors.forename: Nicole
authors.initials: N
authors.lastname: Raus
authors.forename: Jean-Paul
authors.initials: JP
authors.lastname: Fermand
authors.forename: Mauricette
authors.initials: M
authors.lastname: Michallet
authors.forename: Didier
authors.initials: D
authors.lastname: Blaise
authors.forename: Nathalie
authors.initials: N
authors.lastname: Dhédin
mesh_terms: D000328:Adult; D002869:Chromosome Aberrations; D018450:Disease Progression; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality / Q000628:therapy*; D011379:Prognosis; D012189:Retrospective Studies; D014184:Transplantation, Homologous; D016896:Treatment Outcome